Huperzine A - Biscayne Pharmaceuticals

Drug Profile

Huperzine A - Biscayne Pharmaceuticals

Alternative Names: BIS-001; BIS-001ER; INS-001

Latest Information Update: 28 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harvard University
  • Developer Biscayne Pharmaceuticals
  • Class Alkaloids; Neuroprotectants; Nootropics; Sesquiterpenes
  • Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dravet syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Partial epilepsies
  • Phase I Epilepsy

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for phase-I development in Epilepsy in USA
  • 28 Mar 2018 Biscayne Neurotherapeutics and Global Drug Development Centre agree to co-promote and co-develop huperzine A in China, Hong Kong, Macau and Taiwan for Epilepsy
  • 28 Mar 2018 Phase-II clinical trials in Partial epilepsies in Australia (NCT03474770)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top